Boston Scientific offers specialized medical-device franchises, strong cash generation, and recovery potential at a discounted valuation, but cardiovascular weakness, cybersecurity disruption, and Penumbra financing threaten near-term earnings growth.
Medical Devices
31 tickers rated Hold in this themeKnowles benefits from rising demand for specialized defense, medical, and industrial electronic components, supported by strong orders and cash flow, but demanding valuation and manufacturing execution risks limit near-term upside.
Thermo Fisher Scientific combines durable laboratory switching costs, recurring consumables, and recovering biopharma demand with strong cash generation, but demanding valuation and acquisition-related leverage limit near-term upside.
Abbott combines durable medical technology franchises and growing cancer diagnostics exposure with strong cash generation, but acquisition leverage, slowing organic growth and integration risks limit near-term upside.
Johnson & Johnson combines durable pharmaceutical franchises, strong cash generation, and a growing medical innovation portfolio, but elevated valuation, talc liabilities, and MedTech execution risks limit near-term upside.
CooperCompanies offers a discounted entry into durable contact-lens and fertility franchises with strong cash flow and buybacks, but it must normalize U.S. channels and rebuild credibility after the Q3 guidance reset and failed CooperSurgical sale.
Agilent is a high-quality, cash-generative tollbooth in life sciences and analytical instruments with rapid margin expansion, though investors must accept a steep valuation premium amid cyclical biotech capex headwinds and China trade risk.